Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
EsoGuard is now fully reimbursed by Medicare nationwide, and Lucid plans to expand its team to accelerate commercialization.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucid Diagnostics (LUCD) has been named a GenomeWeb 2026 Best Places to Work honoree for the second consecutive year. Employee feedback surveys account for 80% of the program's overall score, with workplace policies and practices accounting for the remaining 20%.
Lucid said EsoGuard is now fully reimbursed by Medicare nationwide and that it plans to expand its team to accelerate commercialization. Lucid is a subsidiary of PAVmed (PAVM).
AI-generated analysis. How Rhea-AI works. Not financial advice.
"Our team's shared passion and relentless dedication to preventing esophageal cancer are the foundation of our success," said Shaun O'Neil, President and Chief Operating Officer of Lucid Diagnostics. "This industry honor is particularly meaningful because it is based on direct feedback solicited from our team members and reflects our culture of collaboration, mutual respect, and commitment to excellence. With EsoGuard now fully reimbursed by Medicare nationwide, this culture will be a powerful asset as we expand our team to accelerate commercialization."
GenomeWeb's annual Best Places to Work program honors companies that foster positive, inclusive workplaces and support professional development. Employee feedback surveys account for
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
About GenomeWeb
GenomeWeb is an independent online news organization based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop advanced tools in molecular biology research and molecular diagnostics. GenomeWeb is a family brand of Crain Communications.
GenomeWeb's editorial mission is to cover the scientific and economic ecosystem enabled by high-throughput genome sequencing, delivering exclusive news and in-depth analysis of the rapidly evolving market. Its audience includes biopharmaceutical companies, research universities, biomedical institutes, clinical laboratories, and government organizations.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-recognized-as-a-genomeweb-best-place-to-work-for-second-consecutive-year-302930663.html
SOURCE Lucid Diagnostics